Barclays
SNOA icon

Barclays’s Sonoma Pharmaceuticals SNOA Stock Holding History

Barclays’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Hold
0
– – – 6773
2019
Q3 		– Hold
0
– – – 7092
2019
Q2 		– Sell
-1
Closed – – 7248
2019
Q1 		$0 Buy
+1
New +$151 ﹤0.01% 7306
2015
Q3 		– Sell
-20
Closed -$18K – 7027
2015
Q2 		$18K Buy
+20
New +$18.7K ﹤0.01% 5745
2014
Q3 		– Sell
-20
Closed -$54K – 7812
2014
Q2 		$54K Buy
+20
New +$59.2K ﹤0.01% 5877

Other funds holding SNOA

BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Barclays's SNOA Position: Q4 2019 in Review

Barclays held its Sonoma Pharmaceuticals (SNOA) position steady in Q4 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6773.

Barclays first reported a position in SNOA in Q2 2014 and has held it in 3 quarters since. The position peaked at $54K in Q2 2014. 13 funds tracked by Wall St. Rank hold SNOA as of Q4 2019.

  • Barclays held 0 shares of Sonoma Pharmaceuticals worth $0 as of Q4 2019.
  • Barclays left its Sonoma Pharmaceuticals share count unchanged in Q4 2019.
  • Sonoma Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q4 2019, its #6773 holding.
  • Barclays first reported a position in Sonoma Pharmaceuticals in Q2 2014 and has held it in 3 quarters since.
  • Barclays's Sonoma Pharmaceuticals position peaked at $54K in Q2 2014.
  • 13 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q4 2019.

Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.